Results 41 to 50 of about 15,339 (211)

Probable respiratory dyskinesia in an elderly patient after sudden stoppage of antipsychotics

Journal of Geriatric Mental Health, 2016
Antipsychotic drugs are widely used in the management of schizophrenia in the elderly. Extrapyramidal reactions to these drugs and tardive dyskinesia are a dreaded side effect of these drugs that may be seen in the elderly. We present herewith, a case of
Vikram Vaidya, Nilesh Shah, Avinash Desousa   +2 more
doaj   +1 more source

Tardive Dyskinesia and Dystonia – Clinical Case Review and Grand Rounds

Journal of Psychiatry Spectrum, 2022
Tardive dyskinesia (TD) syndromes are clinical conditions characterized by abnormal involuntary movements of the body and can range from occasional annoying involuntary movements to debilitating dystonia and are associated with increased mortality rates ...
Satish Suhas, Hariprasad Ganapathy Vijayakumar, Ganesan Venkatasubramanian, Shivarama Varambally   +3 more
doaj   +1 more source

Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis [PDF]

, 2018
Background: Movement disorders (MD) associated with exposure to antipsychotic drugs (AP). MD are common and stigmatising, but underdiagnosed. Methods: We developed a screening procedure for AP-MD for administration by mental health (MH) nurses.
Balint, Bettina, Barnes, Thomas, Bhatia, Kailash, Clarke, Caroline, De Micco, Rosa, Edwards, Mark, Erro, Roberto, Foltynie, Thomas, Foreshaw, Yvonne, Freemantle, Nick, Green, Nicholas, Hunter, Rachel, Joyce, Eileen, Killaspy, Helen, Latorre, Anna, Marston, Louise, Martino, Davide, Nolan, Fiona M, Schrag, Anette   +18 more
core   +3 more sources

The Spectrum of Abnormal Tongue Movements: Review of Phenomenology, Etiology, and Differential Diagnosis

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan, Seyed‐Mohammad Fereshtehnejad, Christos Ganos, Emily Swinkin, Anthony E. Lang   +4 more
wiley   +1 more source

D₂ Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways [PDF]

, 2005
Regulator of G-protein signaling 9-2 (RGS9-2), a member of the RGS family of Gα GTPase accelerating proteins, is expressed specifically in the striatum, which participates in antipsychotic-induced tardive dyskinesia and in levodopa-induced dyskinesia. We
Axelrod, Jeffrey D., Barghshoon, Sami, Chen, Ching-Kang, Cheyette, Benjamin N. R., Ebert, Jana, Kovoor, Abraham, Lester, Henry A., Schwarz, Johannes, Schwarz, Sigrid, Seyffarth, Petra, Simon, Melvin I.   +10 more
core  

Review of nutrition management of pediatric intestinal pseudo‐obstruction

Nutrition in Clinical Practice, EarlyView.
Abstract Chronic intestinal pseudo‐obstruction (CIPO) is a rare, heterogeneous, and debilitating disorder characterized by profound intestinal dysmotility and severe nutrition challenges. Its presentation resembles that of mechanical bowel obstruction, but CIPO occurs in the absence of luminal obstruction.
Senthilkumar Sankararaman, Raisa Rani James, Bushra El‐Amaireh, Andrea Adler, Kadakkal Radhakrishnan, Sujithra Velayuthan   +5 more
wiley   +1 more source

Lurasidone-induced tardive dyskinesia

Annals of Indian Psychiatry, 2022
Lurasidone is a novel atypical antipsychotic with additional antidepressant and pro-cognitive properties. The drug has shown good efficacy in treatment of schizophrenia as well as bipolar disorder.
Shreyas Shrikant Pendharkar, Shilpa Avinash Telgote   +1 more
doaj   +1 more source

A case of tardive dyskinesia with paliperidone palmitate

Telangana Journal of Psychiatry, 2015
Background: Tardive dyskinesia is a neurological side effect of long term antipsychotics use. Incidence is common and found to be less prevalent with second generation antipsychotics than the first generation antipsychotics.
Philip Kumar Boyanapally, Nishanth Vemana, Phani Prasant Mulakaluri   +2 more
doaj   +1 more source

Towards the clinical implementation of pharmacogenetics in bipolar disorder. [PDF]

, 2014
BackgroundBipolar disorder (BD) is a psychiatric illness defined by pathological alterations between the mood states of mania and depression, causing disability, imposing healthcare costs and elevating the risk of suicide.
A Berghofer, A Heils, A Koski, A Serretti, A Serretti, A Serretti, A Szczepankiewicz, A Yu, AA Nierenberg, AK Malhotra, AL Zackrisson, B Alsina, B Kremeyer, C Cordon-Cardo, C Kawanishi, C O’Dushlaine, C Sears, CA Grimes, CC Zai, CE Begley, CH Chen, DA Mrazek, DE Adkins, DJ Smith, DK Hall-Flavin, DK Hall-Flavin, DL Braff, E Lessard, E Schaeffeler, EB Binder, EB Brown, EG Jonsson, EJ Peters, EK Green, EM Penas-Lledo, EM Penas-Lledo, EN Smith, ER Mardis, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, F Asztely, F Benedetti, F Czerwensky, F Holsboer, F Mamdani, FJ Gonzalez, FJ McMahon, FM Daray, FP Bymaster, FP Guengerich, FR Sallee, G Shaltiel, G Turecki, GE Simon, GENDEP Investigators, MARS Investigators, STAR*D Investigators, GR Lewin, GS Malhi, GS Sachs, H Pei, HA Garriock, HK Kroemer, I Johansson, IC Gray, J Brockmoller, J de Leon, J de Leon, J de Leon, J de Leon, J Kirchheiner, J Kirchheiner, J Thome, J Winner, JA Engelman, JA Johnson, JA Lieberman, JC Ballenger, JC Chambers, JC Stingl, JE Kootstra-Ros, JE Sarginson, JK Rybakowski, JK Rybakowski, JM Beaulieu, John R Kelsoe, JP Zhang, JP Zhang, JR Kelsoe, JS Leeder, JT Groves, K Herrlin, K Hodgson, K Yoshii, KG Mountjoy, KL Kopnisky, KR Crews, KW Lobello, L Bertilsson, L Michelon, L Tondo, LA Smith, LN Yatham, LV Kessing, M Adli, M Dmitrzak-Weglarz, M Gex-Fabry, M Ingelman-Sundberg, M Man, M Ramsjo, M Sanford, M Tseng, M Uhr, MA Kohli, MA Martin, MD Ritchie, ME van den Akker-van Marle, MH Tsai, Michael J McCarthy, MJ Arranz, MJ McCarthy, MJ Neville, ML Dahl, Naji C Salloum, OL de Klerk, OV Olesen, P Grof, P Huezo-Diaz, P Sklar, PS Klein, Psychiatric GWAS Consortium Bipolar Disorder Working Group, R Calati, R Hashimoto, RA Philibert, RC Kessler, RH Perlis, RH Perlis, RH Perlis, RH Perlis, RH Weisler, RJ Loos, RM Hirschfeld, RM Post, RS Seelan, S Horstmann, S Kapur, S Kapur, S Mallal, S Paddock, S Steinberg, S Ulrich, SC Sim, SG Leckband, SH Sindrup, SI Hung, SJ Gardiner, SL McElroy, Susan G Leckband, SV Ambudkar, T Bremer, T Masui, T Rau, T Ritchie, T Suppes, TD Gould, TE Klein, TL Horvath, V De Luca, VL Ellingrod, W Steimer, WB Denny, WH Chung, YF Lin, YF Zou, Z Wang, Z Wang   +172 more
core   +3 more sources

Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation

Psychiatry and Clinical Neurosciences, EarlyView.
Aim Vesicular monoamine transporter 2 (VMAT2) inhibitors have been approved for the treatment of tardive dyskinesia (TD), whereas anticholinergic agents are still widely used for this condition. This study aimed to compare the risk of major clinical adverse outcomes among patients with TD treated with VMAT2 inhibitors versus anticholinergic agents ...
Tien‐Wei Hsu, Chih‐Wei Hsu, Ping‐Tao Tseng, Yi‐Ya Fang, Chuo‐Yu Lee, Yu‐Hsuan Lin, Brendon Stubbs, Trevor Thompson, Andre F. Carvalho, Yu‐Chen Kao, Jen‐Ping Chen, Fu‐Chi Yang, Chia‐Kuang Tsai, Chih‐Sung Liang   +13 more
wiley   +1 more source